Leukemia — Chronic Lymphocytic (CLL) Clinical Trials

About Leukemia — Chronic Lymphocytic (CLL) trials

CLL trials are organized around two prognostic axes that have been the basis of risk stratification for two decades: TP53 status and IGHV mutational status. TP53 mutations or del(17p) loss define a high-risk subgroup that is treated and trialed differently from other CLL patients, with continuous BTK inhibitor therapy as the standard of care and trials focused on novel combinations or non-covalent agents. IGHV mutational status (mutated vs unmutated) is a foundational prognostic marker tested at diagnosis. SF3B1 mutations are common in CLL and contribute to risk stratification. BTK mutations are tested specifically in patients who have progressed on covalent BTK inhibitors (resistance mutations like C481S), and gate trials of next-generation BTK inhibitors and BTK degraders.

The CLL trial set divides by treatment line and risk profile. Front-line trials test new combinations and time-limited regimens, comparing continuous BTK inhibitor therapy against venetoclax-based fixed-duration combinations or novel triplets. R/R trials are an active space because patients post-BTK and post-venetoclax now have multiple options without a clear single standard, with non-covalent BTK inhibitors, BTK degraders, BCL-2 combinations, and CAR-T therapy all in trial. High-risk trials enroll TP53-aberrant patients specifically, often combining BTK inhibition with IO, PI3K, or novel mechanisms. Richter transformation trials are a distinct, smaller trial set for patients whose CLL has transformed into aggressive lymphoma (DLBCL or Hodgkin-type). Phase 1 trials test new mechanisms in heavily pretreated patients, often after both BTK and venetoclax exposure.

Beyond biomarkers, CLL trial eligibility depends on prior BTK and venetoclax exposure, IGHV / TP53 status, and treatment intent. Prior BTK inhibitor exposure: most R/R trials specify whether patients are BTK-naïve, BTK-treated, or progressed on BTK. Prior venetoclax exposure has become a similarly defining criterion. IGHV mutational status, TP53 mutation, and del(17p) appear in many trial inclusion or stratification criteria. BTK resistance mutation testing for patients on covalent BTK inhibitors is increasingly required for R/R trials of next-generation agents. Performance status, with most trials accepting ECOG 0-2 because CLL patients are often older. Cytopenias and CIRS comorbidity scoring matter for fitness assessment. Active autoimmune cytopenias may exclude patients from some trials.

Biomarkers tested in Leukemia — Chronic Lymphocytic (CLL) trials

These are the molecular markers most commonly required or evaluated in Leukemia — Chronic Lymphocytic (CLL) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.